Literature DB >> 32741060

Cachexia in Systemic Lupus Erythematosus: Risk Factors and Relation to Disease Activity and Damage.

George Stojan1, Jessica Li1, Amaya Wittmaack2, Michelle Petri1.   

Abstract

OBJECTIVE: Cachexia is a disorder characterized by involuntary weight loss in addition to loss of homeostatic control of both energy and protein balance. Despite an abundance of data from other inflammatory diseases, cachexia in systemic lupus erythematosus (SLE) remains a largely undescribed syndrome. The present study was undertaken to define the prevalence of cachexia in SLE and to identify the main factors that place patients at risk of developing cachexia.
METHODS: A total of 2,452 patients in a prospective SLE cohort had their weight assessed at each visit. Patients were categorized into 5 predetermined groups based on weight. Cachexia was defined based on modified Fearon criteria (5% stable weight loss in 6 months without starvation relative to the average weight in all prior visits and/or a weight loss of >2% without starvation relative to the average weight in all prior cohort visits and a body mass index [BMI] of <20 kg/m2 ). Risk of cachexia within 5 years of cohort entry was based on Kaplan-Meier estimates. The association of prior disease manifestations with risk of cachexia adjusted by current steroid use was determined using Cox regression. An analysis of variance test was used to determine whether Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) scores varied based on cachexia status.
RESULTS: Within 5 years of cohort entry, 56% of patients developed cachexia, 18% of which never recovered their weight during follow-up. The risk factors for cachexia development were a BMI of <20 kg/m2 , current steroid use, vasculitis, lupus nephritis, serositis, hematologic lupus manifestations, positive anti-double-stranded DNA, anti-Sm, and anti-RNP. Patients with intermittent cachexia had significantly higher SDI scores compared to those with continuous cachexia or without cachexia.
CONCLUSION: Cachexia is an underrecognized syndrome in patients with SLE. SLE patients with intermittent cachexia have the highest risk of future organ damage.
© 2020, American College of Rheumatology.

Entities:  

Mesh:

Year:  2021        PMID: 32741060      PMCID: PMC7855238          DOI: 10.1002/acr.24395

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  26 in total

1.  Hopkins Lupus Cohort. 1999 update.

Authors:  M Petri
Journal:  Rheum Dis Clin North Am       Date:  2000-05       Impact factor: 2.670

2.  Definition and treatment of lupus flares measured by the BILAG index.

Authors:  C Gordon; N Sutcliffe; J Skan; T Stoll; D A Isenberg
Journal:  Rheumatology (Oxford)       Date:  2003-06-16       Impact factor: 7.580

3.  Consensus on cachexia definitions.

Authors:  Josep M Argilés; Stefan D Anker; William J Evans; John E Morley; Ken C H Fearon; Florian Strasser; Maurizio Muscaritoli; Vicky E Baracos
Journal:  J Am Med Dir Assoc       Date:  2010-05       Impact factor: 4.669

4.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

5.  Evaluation of TRAF6 in a large multiancestral lupus cohort.

Authors:  Bahram Namjou; Chan-Bum Choi; Isaac T W Harley; Marta E Alarcón-Riquelme; Jennifer A Kelly; Stuart B Glenn; Joshua O Ojwang; Adam Adler; Kwangwoo Kim; Caroline J Gallant; Susan A Boackle; Lindsey A Criswell; Robert P Kimberly; Elizabeth E Brown; Jeffrey Edberg; Graciela S Alarcón; Anne M Stevens; Chaim O Jacob; Gary S Gilkeson; Diane L Kamen; Betty P Tsao; Juan-Manuel Anaya; Eun-Mi Kim; So-Yeon Park; Yoon-Kyoung Sung; Joel M Guthridge; Joan T Merrill; Michelle Petri; Rosalind Ramsey-Goldman; Luis M Vilá; Timothy B Niewold; Javier Martin; Bernardo A Pons-Estel; Timothy J Vyse; Barry I Freedman; Kathy L Moser; Patrick M Gaffney; Adrienne H Williams; Mary E Comeau; John D Reveille; Changwon Kang; Judith A James; R Hal Scofield; Carl D Langefeld; Kenneth M Kaufman; John B Harley; Sang-Cheol Bae
Journal:  Arthritis Rheum       Date:  2012-01-09

Review 6.  Roles of tumour necrosis factor-related weak inducer of apoptosis/fibroblast growth factor-inducible 14 pathway in lupus nephritis.

Authors:  Jingyun Chen; Linlin Wei; Yumin Xia
Journal:  Nephrology (Carlton)       Date:  2017-02       Impact factor: 2.506

7.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

8.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.

Authors:  W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

9.  Cachexia: a new definition.

Authors:  William J Evans; John E Morley; Josep Argilés; Connie Bales; Vickie Baracos; Denis Guttridge; Aminah Jatoi; Kamyar Kalantar-Zadeh; Herbert Lochs; Giovanni Mantovani; Daniel Marks; William E Mitch; Maurizio Muscaritoli; Armine Najand; Piotr Ponikowski; Filippo Rossi Fanelli; Morrie Schambelan; Annemie Schols; Michael Schuster; David Thomas; Robert Wolfe; Stefan D Anker
Journal:  Clin Nutr       Date:  2008-08-21       Impact factor: 7.324

10.  Cachexia in cancer: what is in the definition?

Authors:  Greetje Vanhoutte; Mick van de Wiel; Kristin Wouters; Michaël Sels; Linda Bartolomeeussen; Sven De Keersmaecker; Caroline Verschueren; Veronique De Vroey; Annemieke De Wilde; Elke Smits; Kin Jip Cheung; Liesbeth De Clerck; Petra Aerts; Didier Baert; Caroline Vandoninck; Sofie Kindt; Sofie Schelfhaut; Marc Vankerkhoven; Annelies Troch; Lore Ceulemans; Hanne Vandenbergh; Sven Leys; Tim Rondou; Elke Dewitte; Kristel Maes; Patrick Pauwels; Benedicte De Winter; Luc Van Gaal; Dirk Ysebaert; Marc Peeters
Journal:  BMJ Open Gastroenterol       Date:  2016-10-18
View more
  1 in total

1.  A BAFF/APRIL axis regulates obesogenic diet-driven weight gain.

Authors:  Calvin C Chan; Isaac T W Harley; Paul T Pfluger; Aurelien Trompette; Traci E Stankiewicz; Jessica L Allen; Maria E Moreno-Fernandez; Michelle S M A Damen; Jarren R Oates; Pablo C Alarcon; Jessica R Doll; Matthew J Flick; Leah M Flick; Joan Sanchez-Gurmaches; Rajib Mukherjee; Rebekah Karns; Michael Helmrath; Thomas H Inge; Stuart P Weisberg; Sünje J Pamp; David A Relman; Randy J Seeley; Matthias H Tschöp; Christopher L Karp; Senad Divanovic
Journal:  Nat Commun       Date:  2021-05-18       Impact factor: 14.919

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.